Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Timing the Trade the Wyckoff Way -- Ignore unavailable to you. Want to Upgrade?

To: gunshyinvestor who wrote (13956)	5/1/2016 4:03:08 PM
From: coferspeculator	Read Replies (1) \| Respond to of 14340

been a favorite here from the day listed . . knew and know folks with the disease . . companies that can make major breakthroughs in certain diseases are going to be huge winners . . doesn't mean the ride to big gains will be smooth . very volatile market . . . the volatility is an advantage if you miss out on one or if you want to get back in . . a early fund purchaser of shares now with two seats on the company's board bought another $79 million early this year when shares were near $30 . . . don't think folks sitting on the board were throwing that kind of money at the stock for no good reason . . shares fell below $19 during the biotech blood bath . . of course the technical geniuses were saying there was a big problem . . sadly folks listen to the noise. not sure if the FDA approval wasn't already a foregone conclusion . . evidence for approval was very compelling a few weeks back at $24 . . think if someone is looking for an acquisition the shares will go higher but if the company holds to the idea they want to sell to the market on their own it will take time and money to push prices higher . . my thoughts for what they are worth . .